Skip to main content
Figure 2 | BMC Research Notes

Figure 2

From: Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study

Figure 2

The increase in serum potassium concentration during the first week of treatment was significant and similar for enalapril (n = 20) and olmesartan (n = 27). (A) The effects of both drugs in microalbuminuria (B) and glomerular filtration rate (C) during the trial were also similar between groups. Valid results for e-GFR were obtained for enalapril: n = 22,16,14,14 and for olmesartan: n = 24,24,16,11 for measurements at t = 0, 1, 4, 8 and 12 weeks, respectively. Valid results for microalbuminuria were obtained for enalapril: n = 17,14,10,10 and for olmesartan: n = 24,22,14,12 for measurements at t = 0, 1, 4, 8 and 12 weeks, respectively. *p < 0.05.

Back to article page